Portal de Periódicos da CAPES

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

2021; European Centre for Disease Prevention and Control; Volume: 26; Issue: 16 Linguagem: Inglês

10.2807/1560-7917.es.2021.26.16.2100348

1560-7917

Tjede Funk, Anastasia Pharris, Gianfranco Spiteri, Nick Bundle, Angeliki Melidou, Michael J. Carr, Gabriel González, A. Léon, Fiona Crispie, Lois O’Connor, Niamh Murphy, Joël Mossong, Anne Vergison, Anke Wienecke-Baldacchino, Tamer Abdelrahman, Flavia Riccardo, Paola Stefanelli, Angela Di Martino, Antonino Bella, Alessandra Lo Presti, Pedro Casaca, Joana Moreno, Vítor Borges, Joana Isidro, Rita Ferreira, João Paulo Gomes, Liidia Dotsenko, Heleene Suija, Jevgenia Epštein, Olga Sadikova, Hanna Sepp, Niina Ikonen, Carita Savolainen‐Kopra, Soile Blomqvist, Teemu Möttönen, Otto Helve, Joana Gomes-Dias, Cornelia Adlhoch,

COVID-19 Clinical Research Studies

We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, 95% CI: 2.1–6.2; P.1: 2.6, 95% CI: 1.4–4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4–3.5; P.1: 2.2, 95% CI: 1.7–2.8).